Results 201 to 210 of about 237,110 (353)

Preoperative Detection of Dual TERT Promoter Mutations in Thyroid Cancer: A Case Series

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Telomerase reverse transcriptase promoter (TERTp) mutations are associated with aggressive thyroid cancer and are most frequently found in anaplastic and poorly differentiated thyroid cancer. Pre‐operative thyroid nodule molecular testing can detect TERTp, denoting a high risk of malignancy and possible aggressive clinical features such as ...
Amir Harari   +7 more
wiley   +1 more source

Tumor diversity and evolution revealed through RADseq [PDF]

open access: yes, 2017
Altshuler   +66 more
core   +2 more sources

Broadening the Genetic Spectrum of Painful Small-Fiber Neuropathy through Whole-Exome Study in Early-Onset Cases [PDF]

open access: gold
Kaalindi Misra   +13 more
openalex   +1 more source

Correction to: Exome sequencing reveals a novel PLP1 mutation in a Moroccan family with connatal Pelizaeus-Merzbacher disease: a case report [PDF]

open access: gold, 2018
Jaber Lyahyai   +10 more
openalex   +1 more source

Whole‐exome sequencing uncovers new variants in GDF15 associated with hyperemesis gravidarum

open access: green, 2022
Marlena S. Fejzo   +4 more
openalex   +2 more sources

The role of Rho GTPases in facial morphogenesis

open access: yesDevelopmental Dynamics, EarlyView.
The role of small GTPases, RHOA, RAC1, and CDC42 and pathway mediators is reviewed in the context of embryonic facial development. Lip fusion requires cytoskeletal remodeling during morphogenesis of the facial processes and during lip fusion. Fnm, frontonasal mass; lnp, lateral nasal process; mnp, medial nasal process; mxp, maxillary process; np, nasal
Isra Ibrahim, Joy M. Richman
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy